Integration of postpartum healthcare services for HIV-infected women and their infants in South Africa: A randomised controlled trial by Myer, Landon et al.
RESEARCH ARTICLE
Integration of postpartum healthcare services
for HIV-infected women and their infants in
South Africa: A randomised controlled trial
Landon Myer1,2*, Tamsin K. Phillips1,2, Allison Zerbe3, Kirsty Brittain1,2, Maia Lesosky1,
Nei-Yuan Hsiao4,5, Robert H. Remien6, Claude A. Mellins6, James A. McIntyre1,7, Elaine
J. Abrams3,8,9
1 Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape
Town, Cape Town, South Africa, 2 Centre for Infectious Diseases Epidemiology and Research, School of
Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa, 3 ICAP at Columbia
University, Mailman School of Public Health, Columbia University, New York, New York, United States of
America, 4 National Health Laboratory Service, Cape Town, South Africa, 5 Division of Medical Virology,
University of Cape Town, Cape Town, South Africa, 6 HIV Center for Clinical and Behavioral Studies, New
York State Psychiatric Institute, New York, New York, United States of America, 7 Anova Health Institute,
Johannesburg, South Africa, 8 College of Physicians and Surgeons, Columbia University, New York, New
York, United States of America, 9 Department of Epidemiology, Mailman School of Public Health, Columbia




As the number of HIV-infected women initiating lifelong antiretroviral therapy (ART) during
pregnancy increases globally, concerns have emerged regarding low levels of retention in
HIV services and suboptimal adherence to ART during the postpartum period. We examined
the impact of integrating postpartum ART for HIV+ mothers alongside infant follow-up within
maternal and child health (MCH) services in Cape Town, South Africa.
Methods and findings
We conducted a randomised trial among HIV+ postpartum women aged18 years who ini-
tiated ART during pregnancy in the local antenatal care clinic and were breastfeeding when
screened before 6 weeks postpartum. We compared an integrated postnatal service among
mothers and their infants (the MCH-ART intervention) to the local standard of care (control)
—immediate postnatal referral of HIV+ women on ART to general adult ART services and
their infants to separate routine infant follow-up. Evaluation data were collected through
medical records and trial measurement visits scheduled and located separately from health-
care services involved in either arm. The primary trial outcome was a composite endpoint of
women’s retention in ART care and viral suppression (VS) (viral load < 50 copies/ml) at 12
months postpartum; secondary outcomes included duration of any and exclusive breast-
feeding, mother-to-child HIV transmission, and infant mortality. Between 5 June 2013 and
10 December 2014, a total of 471 mother–infant pairs were enrolled and randomised (mean
age, 28.6 years; 18% nulliparous; 57% newly diagnosed with HIV in pregnancy; median
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duration of ART use at randomisation, 18 weeks). Among 411 women (87%) with primary
endpoint data available, 77% of women (n = 155) randomised to the MCH-ART intervention
achieved the primary composite outcome of retention in ART services with VS at 12 months
postpartum, compared to 56% of women (n = 117) randomised to the control arm (absolute
risk difference, 0.21; 95% CI: 0.12–0.30; p < 0.001). The findings for improved retention in
care and VS among women in the MCH-ART intervention arm were consistent across sub-
groups of participants according to demographic and clinical characteristics. The median
durations of any breastfeeding and exclusive breastfeeding were longer in women rando-
mised to the intervention versus control arm (6.9 versus 3.0 months, p = 0.006, and 3.0 ver-
sus 1.4 months, p < 0.001, respectively). For the infants, overall HIV-free survival through
12 months of age was 97%: mother-to-child HIV transmission was 1.2% overall (n = 4 and n
= 1 transmissions in the intervention and control arms, respectively), and infant mortality
was 1.9% (n = 6 and n = 3 deaths in the intervention and control arms, respectively), and
these outcomes were similar by trial arm. Interpretation of these findings should be qualified
by the location of this study in a single urban area as well as the self-reported nature of
breastfeeding outcomes.
Conclusions
In this study, we found that integrating ART services into the MCH platform during the post-
natal period was a simple and effective intervention, and this should be considered for




Why was this study done?
• More than 1 million HIV-infected women of reproductive age become pregnant glob-
ally each year, and World Health Organization policies call for initiation of lifelong anti-
retroviral therapy (ART) in all HIV-infected pregnant and breastfeeding women.
• However, keeping HIV-infected women retained in care, adherent to ART, and with
HIV viral suppression is a major public health challenge, particularly postpartum.
• Integration of ART services into existing maternal and child health (MCH) programmes
is one intervention approach that has been widely discussed to address this challenge,
but this approach has not been rigorously evaluated.
What did the researchers do and find?
• Working in Cape Town, South Africa, we recruited immediately postpartum 471 HIV-
infected, breastfeeding women who had initiated ART during pregnancy.
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• We randomised mother–infant pairs to either referral to general adult ART clinics, with
their children referred to child health clinics (the local standard of care, which acted as a
control condition), or keeping mothers and infants in care together in an MCH-focused
ART service (the intervention).
• We followed mother–infant pairs through 12 months postpartum with regular study
visits that were scheduled and conducted independent of routine services in either the
intervention or control arms; batched viral load testing was conducted at these study
visits, separate from routine care.
• We found that women randomised to the integrated care intervention had higher levels
of retention in care and viral suppression through 12 months postpartum. This differ-
ence was observed in all subgroups of women, including younger and older women,
those newly diagnosed with HIV, those with lower CD4 cell counts, and those with lon-
ger durations of ART use before delivery.
• Women in the integrated care intervention also reported breastfeeding their infants for
longer periods. Levels of infant mortality and mother-to-child HIV transmission were
low and similar between the intervention and control arms.
What do these findings mean?
• Integrating MCH and ART services appears effective in keeping HIV-infected mothers
retained in care and virally suppressed.
• Integrated services may also contribute to longer durations of breastfeeding, and thus
contribute to child health.
• These data should be interpreted carefully, as they come from a single part of South
Africa, and further research is needed to examine the generalisability of the findings to
other settings.
Introduction
The past decade has witnessed a paradigm shift in the science of and services for prevention of
mother-to-child HIV transmission (PMTCT) [1,2]. Lifelong triple-drug antiretroviral therapy
(ART) for all women living with HIV regardless of disease status (per the World Health Orga-
nization’s Option B+ approach) has emerged as the standard for reducing vertical HIV trans-
mission and promoting maternal health [3]. With this approach, there have been substantial
increases globally in ART use by HIV+ pregnant and postpartum women, with consequent
reductions in new paediatric HIV infections, providing a potent example of the synergies of
ART use for HIV treatment and prevention [4].
Alongside the successes of universal ART for pregnant and postpartum women, multiple
studies from around the world have raised major concerns regarding low levels of retention in
HIV services and adherence to ART medications in this population [5–8]. These findings
appear especially marked in the postpartum period and contribute directly to failures in main-
taining viral suppression (VS) [8,9]. This limits the benefits of ART, and, in turn, there is an
urgent need to help HIV+ women to remain engaged in ART services over the long term.
Integrated MCH and ART services for postpartum care
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Moreover, with new WHO guidelines recommending that HIV+ mothers breastfeed for at
least 12 months postpartum [10], the ability of health services to support mothers on ART has
direct implications for the health of their HIV-exposed infants. Yet there have been few rigor-
ous evaluations of interventions to promote postpartum engagement in ART services, and
existing evaluations have been limited in their duration of follow-up [11].
Related to this, there has been a call for integrating HIV care and treatment services into
the broader platform of primary healthcare, particularly in the context of PMTCT [12]. Inte-
gration of ART into antenatal care (ANC) services has proven critical to the successful delivery
of ART to pregnant women under Option B+ across sub-Saharan Africa [13]. However, there
has been little consideration given to the integration of health services during the postpartum
period, when HIV+ women’s retention and adherence may be under greatest threat. In many
settings, women initiating ART as part of ANC are referred immediately post-delivery to gen-
eral adult ART services [14,15]. This change in the location of care and the separation of
maternal and infant services has been a point of loss to follow-up, and there may be a major
missed opportunity for linking ART services within the broader maternal and child health
(MCH) care platform. To address this gap, we examined the impact of integrating postpartum
ART for HIV+ mothers and infant follow-up within MCH services on maternal retention in
care and VS through 12 months postpartum in Cape Town, South Africa.
Methods
Design and setting
We conducted a parallel-arm randomised trial comparing an integrated postnatal care service
within the MCH setting for HIV+ mothers and their infants (the MCH-ART intervention) to
the local standard of care (SOC, control)—immediate postnatal referral of HIV+ women on
ART to general adult ART services and their infants to routine infant follow-up. The trial took
place in a subdistrict of Cape Town as described previously [16]. Within the subdistrict, the
study was based at a large, primary-level antenatal and obstetric facility located in a commu-
nity of approximately 300,000 where levels of both poverty and HIV infection are high; referral
was to one of a number of primary care services in the subdistrict [17]. The study was regis-
tered on ClinicalTrials.gov (NCT01933477); final registration was approved 3 months after the
start of enrolment due to an administrative error. The study protocol is provided as S1 Text.
The study protocol was approved by the Human Research Ethics Committee of the University
of Cape Town Faculty of Health Sciences, as well as by the Institutional Review Board of
Columbia University Medical Center.
Routine PMTCT and ART services
In this setting, routine ANC is provided in the MCH clinic and includes PMTCT services with
nurse-midwives initiating women on ART and providing follow-up with support from coun-
sellors. ART eligibility is based on local public sector guidelines. For women making their first
ANC visit before July 2013, eligibility was based on CD4 cell count 350 cells/μl or WHO
stage III/IV disease, per WHO 2010 recommendation Option A. From July 2013, all HIV
+ pregnant women were ART eligible (WHO 2013 recommendation Option B+) [18]. All
women initiated the local first-line ART regimen of tenofovir (300 mg) + emtricitabine (200
mg)/lamivudine (300 mg) + efavirenz (600 mg) provided as a fixed-dose combination pill
taken once daily. For all women in the study, ART initiation, all clinical care, and infant fol-
low-up was provided by government health services based on public sector policies. Routine
infant HIV diagnostic testing in this setting, based on nucleic acid amplification tests, was car-
ried out at 6–10 weeks of age.
Integrated MCH and ART services for postpartum care
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Participants and eligibility
Participants were HIV+ women and their infants (regardless of HIV infection status) recruited
immediately postpartum during routine clinical follow-up visits. As part of a larger implemen-
tation science study, all HIV+ women seeking ANC who were eligible for enrolment were
interviewed and followed from their first ANC visit. To be eligible for the trial, women were
required to be at least 18 years of age and less than 6 weeks postpartum, to have initiated ART
during the recently completed pregnancy (regardless of previous antiretroviral [ARV] expo-
sure or evidence of VS), and to be breastfeeding their infants at the time of screening.
Randomisation
After providing written informed consent, eligible mother–infant pairs were allocated 1:1 to
the intervention or control arm via computer-generated block randomisation with dynami-
cally permuted block sizes from 2 to 8. Allocations were via opaque sealed envelopes kept
securely and accessed by the study coordinator. The study coordinator communicated the ran-
dom allocation to nurse-midwives in the MCH clinic via a standardised letter.
MCH-ART intervention
Women randomised to the intervention continued to receive postnatal care in the MCH clinic
for the duration of breastfeeding, with care provided to their HIV-exposed infants in the same
service. As part of this, nurse-midwives provided ongoing HIV-specific services (including
ART and routine infant HIV diagnostic testing) in addition to general care (including contra-
ception for mothers and routine infant care such as anthropometry and vaccinations). At each
postnatal visit, nurse-midwives asked mothers about their infant feeding; when mothers
reported having stopped breastfeeding, nurse-midwives conducted additional infant HIV
diagnostic testing per local guidelines and referred mother–infant pairs out of the MCH clinic,
although study-specific follow-up persisted regardless of the site of care.
SOC control
Women and their infants randomised to the control arm followed the local SOC, with referral
out of the MCH clinic—to general adult ART services for the mother and “well baby” (child
health) services for the infant—by nurse-midwives as soon as possible postpartum, typically at
their first postnatal visit.
Referrals
For both the intervention and control arms, referrals out of the MCH clinic followed routine
local practice. Women were counselled on ART adherence, infant feeding and care including
HIV testing, and related aspects of maternal and infant health. They were provided with a
referral letter to attend the ART clinic of their choosing (typically based on area of residence)
and dispensed a 1-month supply of ART. Mothers were advised to take infants as soon as pos-
sible to their nearest routine child health services, which incorporated care for HIV-exposed
infants.
Counselling and patient support
Under both the intervention and control conditions, ART counselling was provided by the rou-
tine public sector ART counsellors based either in the MCH clinic (intervention) or general
adult ART services (control). These counsellors undergo standardised training and supervision;
Integrated MCH and ART services for postpartum care
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throughout the study, counselling messages and frequency were based on local standards with-
out adaptation in either the intervention or control arm.
Missed clinic visits
Procedures for tracing women who did not attend a scheduled clinic appointment in either
the intervention or control arm were based on local public sector norms: as feasible according
to available information and clinic workloads, clinic personnel attempted to contact patients
who missed a clinic visit via telephone and/or home visit.
Sources of data
Evaluation data were collected through a series of trial measurement visits scheduled and
located separately from the public sector healthcare services involved in either arm of the trial.
Visits took place at 6 weeks and then 3, 6, 9, and 12 months postpartum. For attendance at
each trial measurement visit, women received R 150 (approximately US$12) in a combination
of food vouchers and/or child-related consumables (such as diapers or clothing); no reim-
bursement was provided for attendance at routine healthcare visits in either the intervention
or control arm.
At the start of each measurement visit, participating mothers were instructed to not disclose
to study personnel where they were receiving HIV care, and questionnaires did not investigate
this. Mothers provided 5 ml of venous blood at each study visit for batched HIV RNA viral
load (VL) testing by the South African National Health Laboratory Services (NHLS) using the
Abbott RealTime HIV-1 assay (Abbott Laboratories, Abbott Park, Illinois, US); this testing
was conducted independently from routine VL monitoring for patients on ART. At the
12-month study visit, infants underwent phlebotomy for HIV PCR testing at NHLS using the
Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assay (Roche Diagnostics, Branchburg,
New Jersey, US). In the event of missed trial measurement visits, participants were traced by a
study fieldworker working independently of routine healthcare services.
Additional data on maternal and infant use of healthcare services were drawn from rou-
tinely collected public sector medical records, abstracted for all participants at the end of the
study period. Data sources for this were identical across facilities involved in both arms of the
trial and included medical record review at all care facilities (both from folders and electronic
medical records, when available, and including infants’ Road to Health Booklets), provincial
electronic pharmacy dispensing records, and centralised NHLS databases of laboratory tests.
Outcomes
The primary trial outcome was a composite endpoint of women’s retention in ART care and
VS (VL< 50 copies/ml based on VL testing at trial measurement visit) at 12 months postpar-
tum. Retention in care at 12 months postpartum was measured using routinely collected medi-
cal records and defined as evidence of an HIV-related clinical contact from the period 9–18
months postpartum. Data used to define a clinical contact came from routinely collected rec-
ords of ARV dispensing, HIV-related laboratory testing, and clinical care visits. In sensitivity
analyses, we examined (i) alternate window periods used to define 12-month retention and (ii)
whether the source of retention data influenced trial findings. Secondary outcomes included
the separate components of the primary outcome, time to loss of VS, duration of any breast-
feeding and exclusive breastfeeding (EBF), infant engagement in appropriate care including
HIV testing and use of ARV prophylaxis, maternal family planning use, mother-to-child HIV
transmission, and infant mortality. Because outcome data on retention in ART care came
from medical records and did not require separate study follow-up, this outcome was available
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for all participants (regardless of completion of trial measurement visits and availability of VL
outcome data) and is presented for all women enrolled as well as restricted to women who also
had VL outcome data.
Statistical analysis
The trial sample size was based on a superiority comparison using 90% power and a 2-sided
alpha at 0.05. With 1:1 randomisation, we aimed to detect an absolute difference in the pri-
mary outcome between trial arms of at least 15%, based on an estimated 90% and 75% of
women retained in care and virally suppressed in the MCH-ART and SOC arms, respectively.
With an estimated 20% loss to follow-up from the trial by 12 months postpartum, we calcu-
lated that approximately 390 women would need to be randomised. When local PMTCT poli-
cies changed from Option A to Option B+ in July 2013, we revised the target sample size to be
based on 390 women initiating ART under Option B+ but continued to follow up women
enrolled in the trial who initiated ART under Option A.
Analyses used Stata version 13.0 (StataCorp, College Station, Texas, US) and R (R Founda-
tion for Statistical Computing, Vienna, Austria). Throughout, results are presented both for all
women enrolled and those initiating ART under Option B+; because findings did not differ
between these two groups, we focus primarily on the total randomised population. Unless oth-
erwise specified, all analyses are by intention to treat. Variables were described using means
(with standard deviations), medians (with interquartile ranges), and proportions (with 95%
confidence intervals). We used rank-sum and chi-squared (replaced in the case of sparse data
by Fisher’s exact) tests for bivariate analyses; all statistical tests are 2-sided at α = 0.05. Prod-
uct-limit methods were used for time-to-event analyses, with the log-rank test used to compare
survival times. VS was defined as VL< 50 copies/ml for the primary outcome, with additional
analyses for VL< 1,000 copies/ml based on international guidelines. Additive binomial regres-
sion models [19] were used to examine the effect of trial arm on the primary outcome after
adjusting for participant clinical and demographic characteristics; results are presented as
absolute risk differences with 95% CIs. Covariates for consideration in these models were
selected based on a priori plausibility in predicting either component of the composite end-
point, while not being plausible causal intermediates of any intervention effect; we included in
the final model those covariates whose inclusion altered the association of interest (the main
trial effect) or which appeared independently associated with the outcome. To examine the
potential influence of missing VL outcome data, multiple imputation via chained equations
was used to create 25 datasets with complete composite endpoint data for use in sensitivity
analyses [20]. Estimates and CIs for imputed data analyses were pooled using Rubin’s rules
[21].
Results
Between 5 June 2013 and 10 December 2014, a total of 587 women were screened postpartum
for inclusion in the trial, of whom 471 were enrolled and randomised (Fig 1). The main rea-
sons for ineligibility of postpartum mother–infant pairs were the mother’s decision not to
breastfeed (13%) or presentation outside the 6-week eligibility window (4%); 8 refusals were
noted (1%). Of the 471 breastfeeding mother–infant pairs randomised into the trial at a
median of 5 days postpartum (IQR, 4–7), 381 (81%) initiated ART under Option B+.
Characteristics at randomisation
Table 1 shows pre-ART and immediate postpartum characteristics by allocation of women to
trial arms, overall and restricted to women enrolled under Option B+. At the first ANC visit,
Integrated MCH and ART services for postpartum care
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the mean age was 28.6 years, 18% of women (n = 87) were nulliparous, and the median gesta-
tional age at the start of ANC was 21 weeks (IQR, 16–27). The median CD4 cell count was 354
cells/μl (IQR, 248–517), and the median log10 VL was 4.0 copies/ml (IQR, 3.4–4.6). At the time
of randomisation, women had been on ART for a median duration of 18 weeks (IQR, 12–23),
76% (n = 355) were suppressed to VL< 50 copies/ml, and 6% of women (n = 29) had
VL 1,000 copies/ml. By design, 100% of women were breastfeeding at randomisation, and
91% (n = 430) reported EBF.
Referral out of the MCH service
Fig 2 shows the distribution of time to referral out of the MCH service in the SOC versus
MCH-ART arm. Among the 238 postpartum women (51%) allocated to be referred out of the
MCH clinic immediately per SOC, the median time to referral out was 11 days (IQR, 1–21),
and 90% of women were referred out within 30 days of delivery to 1 of 18 ART clinics.
Women allocated to the intervention MCH-ART arm were retained in the MCH service until
a median of 32 (IQR, 10–51) weeks postpartum.
Fig 1. Study enrolment, randomisation, and follow-up.
https://doi.org/10.1371/journal.pmed.1002547.g001
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Table 1. Baseline characteristics of the study sample.
Characteristic ART initiation under Option B+ (n = 381) ART initiation under Option A and Option B+ (all




service (n = 186)
Control: standard of
care (n = 195)
Intervention: MCH-ART
service (n = 233)
Control: standard of
care (n = 238)
At first antenatal clinic visit
Mean age (SD), years 28.9 (5.3) 28.3 (5.7) 28.6 (5.3) 28.5 (5.6) 28.6 (5.4)
Home language: isiXhosa 178 (96%) 191 (98%) 223 (96%) 233 (98%) 456 (97%)
Nulliparous 34 (18%) 35 (18%) 42 (18%) 45 (19%) 87 (18%)
Median gestational age at first
ANC visit [IQR]
21 [16, 27] 21 [16, 27] 21 [16, 26] 21 [16, 27] 21 [16, 27]
Timing of first ANC visit
First trimester 33 (18%) 34 (17%) 40 (17%) 40 (17%) 80 (17%)
Second trimester 107 (58%) 114 (58%) 142 (61%) 140 (59%) 282 (60%)
Third trimester 46 (25%) 47 (24%) 51 (22%) 58 (24%) 109 (23%)
Completed secondary/any
tertiary education
43 (23%) 51 (26%) 53 (23%) 64 (27%) 117 (25%)
Currently employed 74 (40%) 73 (37%) 96 (41%) 88 (37%) 184 (39%)
Married/cohabiting 80 (43%) 70 (36%) 99 (42%) 94 (40%) 193 (41%)
Newly diagnosed HIV+ in this
pregnancy
100 (54%) 117 (60%) 127 (55%) 141 (59%) 268 (57%)
Previous antiretrovirals: any 52 (28%) 47 (24%) 67 (29%) 61 (26%) 128 (27%)
Previous ART 8 (4%) 6 (3%) 11 (5%) 8 (3%) 19 (4%)
Previous zidovudine only 47 (25%) 42 (22%) 59 (25%) 54 (23%) 113 (24%)
Previous nevirapine 1 (0.5%) 2 (1%) 2 (0.9%) 4 (2%) 6 (1%)
Previous tuberculosis diagnosis 17 (9%) 16 (8%) 26 (11%) 26 (11%) 52 (11%)
Median CD4 count [IQR]; n =
459
348 [238, 507] 411 [279, 571] 327 [228, 486] 380 [260, 540] 354 [248,
517]
CD4 count
200 cells/μl 30 (17%) 24 (13%) 40 (18%) 34 (15%) 74 (16%)
201–350 cells/μl 61 (34%) 51 (27%) 82 (36%) 69 (30%) 151 (33%)
>350 cells/μl 89 (49%) 114 (60%) 105 (46%) 129 (56%) 234 (51%)
Median log10 HIV VL [IQR] 4.0 [3.5, 4.6] 3.9 [3.1, 4.3] 4.0 [3.5, 4.6] 3.9 [3.2, 4.5] 4.0 [3.4,
4.6]
Log10 HIV VL
<1,000 copies/ml 26 (14%) 41 (21%) 30 (13%) 47 (20%) 77 (16%)
1,000 to <10,000 copies/ml 69 (37%) 72 (37%) 81 (35%) 83 (35%) 164 (35%)
10,000 to <100,000 copies/ml 73 (39%) 64 (33%) 98 (42%) 84 (35%) 182 (39%)
100,000 copies/ml 18 (10%) 18 (9%) 24 (10%) 24 (10%) 48 (10%)
At trial enrolment and
randomisation
Median time on ART [IQR],
weeks
18.1 [11.6, 22.7] 18.0 [12.1, 23.3] 18.6 [11.9, 22.6] 17.7 [12.1, 23.0] 18.0 [12.0,
22.9]
Initiated ART on day of first
antenatal clinic visit
151 (81%) 170 (87%) 161 (69%) 178 (75%) 339 (72%)
Median days postpartum [IQR] 5 [4, 7] 5 [4, 8] 5 [4, 7] 5 [4, 8] 5 [4, 8]
Delivery
In primary care 78 (42%) 76 (39%) 91 (39%) 95 (40%) 186 (39%)
Hospital care 102 (55%) 112 (57%) 136 (58%) 135 (57%) 271 (58%)
Born out of facility 6 (3%) 7 (4%) 6 (3%) 8 (3%) 14 (3%)
Missed ART dose reported in
previous 30 days
30 (16%) 29 (15%) 33 (14%) 31 (13%) 64 (14%)
(Continued)
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Follow-up in trial measurement visits
All women participating in the trial, regardless of trial arm, were followed with separate trial
measurement visits up to 12 months postpartum through 21 January 2016. During this time,
59 women (13%) were lost from scheduled trial measurement visits (independent of their
retention in routine HIV care), including 5 women who withdrew (1%) and 1 maternal death
(<1%). Of the 412 women who completed the study outcome visit, 1 woman was missing VL
measurement, and thus 411 women were available for the primary outcome (87% of those ran-
domised; Fig 1). There was no difference in the completion of trial follow-up and availability
Table 1. (Continued)
Characteristic ART initiation under Option B+ (n = 381) ART initiation under Option A and Option B+ (all




service (n = 186)
Control: standard of
care (n = 195)
Intervention: MCH-ART
service (n = 233)
Control: standard of
care (n = 238)
VL at randomisation (n = 470)
<50 copies/ml 135 (73%) 150 (77%) 171 (73%) 184 (78%) 355 (76%)
50 to <1,000 copies/ml 37 (20%) 35 (18%) 43 (18%) 43 (18%) 86 (18%)
1,000 copies/ml 14 (8%) 9 (5%) 19 (8%) 10 (4%) 29 (6%)
Breastfeeding infant at time of
randomisation
186 (100%) 195 (100%) 233 (100%) 238 (100%) 471 (100%)
Exclusively breastfed infant up to
randomisation
169 (91%) 177 (91%) 211 (91%) 219 (92%) 430 (91%)
Data given as number (percent) unless otherwise indicated.
ANC, antenatal care; VL, viral load.
https://doi.org/10.1371/journal.pmed.1002547.t001
Fig 2. Time to referral out of the maternal and infant health (MCH) service for women in the intervention and
control arms. Log-rank test, p< 0.001.
https://doi.org/10.1371/journal.pmed.1002547.g002
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of VL outcome data by trial arm or PMTCT option, but on average women who completed the
12-month trial measurement visit were older, were less likely to be diagnosed with HIV during
their most recent pregnancy, and entered ANC at an earlier gestational age, compared to
women lost from scheduled trial measurement visits (S1 Table). The median duration of ART
use at the time of outcome assessment was 15.9 months (IQR, 14.5–17.3; median, 16.1 and
15.9 months in the intervention and control arms, respectively).
Primary outcome
Table 2 compares the primary outcome overall and in its constituents between the trial arms,
and shows almost identical results in the Option B+ population and the total trial population.
Among the 411 women in the total trial population who completed trial follow-up and had VL
data available, 77% of women (n = 155) randomised to the MCH-ART arm achieved the pri-
mary composite outcome of retention in ART services with VL< 50 copies/ml at 12 months
postpartum, compared to 56% (n = 117) of women randomised to the SOC arm (risk differ-
ence, 0.21; 95% CI: 0.12–0.30; risk ratio, 1.37; 95% CI: 1.19–1.58; p< 0.001). Within this com-
posite outcome, 80% of women (n = 330) had evidence of retention in ART services at 12
months postpartum: 88% (n = 178) in the MCH-ART arm and 72% (n = 151) in the SOC arm
(p< 0.001). When the analytic population for the retention outcome was extended to all 471
women randomised (regardless of the availability of VL data), these proportions were 81% and
71%, respectively (p = 0.013). The observed differences between the MCH-ART and SOC arms
persisted, for both retention in care and VS, under various definitions of these outcomes. For
example, 80% of women (n = 162) in the MCH-ART arm and 68% (n = 142) in the SOC arm
had VL < 1,000 copies/ml at the study outcome visit (p = 0.005), and the median times to
VL 50 and VL 1,000 copies/ml, among those with VL < 50 copies/ml at randomisation,
were significantly longer among women in the MCH-ART arm compared to women in the
SOC arm (S1 and S2 Figs). Moreover, the findings related to retention did not differ apprecia-
bly by the data source or window period used to define retention (Tables 2 and S2).
The overall findings for superior retention in care and virologic outcomes among women
in the MCH-ART arm appeared consistent across subgroups of participants according to
demographic and clinical characteristics (Figs 3, S3 and S4). Of note, the strongest intervention
effects were observed in women initiating ART during the third trimester of pregnancy (risk
difference, intervention minus control, 42%) compared to the second and first trimesters (risk
differences, 16% and 4%, respectively). In a multivariable model (Table 3), the overall differ-
ence in the primary outcome between intervention and control persisted. In addition, ART
initiation later in pregnancy, previous diagnosis with tuberculosis infection, and increased VL
at the time of randomisation were associated with decreased VS and/or retention postpartum.
In a secondary analysis with missing VL outcome data imputed, the observed differences
between the intervention and control arms persisted (S3 Table).
Effect of duration of MCH-ART service
S4 Table compares outcomes among women randomised to the intervention who were
retained in the MCH-ART service for different durations postpartum. Women randomised to
the intervention who stopped breastfeeding and were referred out within 3 months postpar-
tum had VL and ART retention outcomes measured at 12 months postpartum that were simi-
lar to those of women randomised to the control arm. Conversely, women who breastfed and
were retained for longer periods in the MCH-ART service experienced improvements in out-
comes measured at 12 months postpartum in a graded manner, with the largest intervention
effects observed in women retained for at least 9 months postpartum; this trend persisted after
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adjusting for demographic and clinical covariates (S5 Table). Among women in the interven-
tion arm, each additional month spent in the integrated MCH-ART service was associated
with a 2.5% increase (95% CI: 1.9%–3.1%) in the absolute risk of being retained in care and
virally suppressed at 12 months postpartum in adjusted models.
Secondary outcomes
Patterns of breastfeeding during the study differed between women randomised to the inter-
vention and control arms (Figs 4 and 5). The median duration of any breastfeeding was longer
Table 2. Comparison of primary outcome and variants between trial arms through 12 months postpartum.


















Composite endpoint: evidence of maternal
retention in HIV care and VL < 50 copies/ml at
12 months postpartum (n = 411)
126 (79%) 97 (57%) <0.001 155 (77%) 117 (56%) <0.001 272 (66%)
Retention in care (in all participants enrolled, n
= 471)
Evidence of engagement in HIV care at 12 months
postpartum from any source
150 (81%) 136 (70%) 0.018 188 (81%) 168 (71%) 0.013 356 (76%)
Evidence of engagement in HIV care at 12 months
postpartum by data source
Clinic records 128 (69%) 93 (48%) <0.001 160 (69%) 117 (49%) <0.001 277 (59%)
Laboratory records 126 (68%) 119 (61%) 0.199 158 (68%) 148 (62%) 0.210 306 (65%)
Pharmacy refill 126 (68%) 104 (53%) 0.005 160 (69%) 130 (55%) 0.002 290 (62%)
Retention in care (in all participants retained at
outcome visit with VL data available, n = 411)
Evidence of engagement in HIV care at 12 months
postpartum from any source
141 (88%) 122 (71%) <0.001 178 (88%) 151 (72%) <0.001 329 (80%)
Evidence of engagement in HIV care at 12 months
postpartum by data source
Clinic records 123 (77%) 86 (50%) <0.001 155 (77%) 109 (52%) <0.001 264 (64%)
Laboratory records 117 (73%) 106 (62%) 0.035 148 (73%) 132 (63%) 0.034 280 (68%)
Pharmacy refill 121 (76%) 97 (57%) <0.001 155 (77%) 121 (58%) <0.001 276 (67%)
VL (in all participants retained at outcome visit
with VL data available, n = 411)
<50 copies/ml at 12 months postpartum 126 (79%) 97 (57%) <0.001 155 (77%) 117 (56%) <0.001 272 (66%)
<1,000 copies/ml at 12 months postpartum 132 (83%) 118 (69%) 0.005 162 (80%) 142 (68%) 0.005 304 (74%)
Loss of viral suppression among participants
with VL < 50 copies/ml at randomisation
(n = 312)
Cumulative percent with at least 1 VL 50 copies/
ml through 12 months postpartum
23% 46% 0.011 25% 47% 0.003 37%
Cumulative percent with at least 1 VL 1,000
copies/ml through 12 months postpartum
17% 34% 0.006 17% 34% 0.002 26%
Two consecutive VL 50 copies/ml through 12
months postpartum
14 (12%) 36 (28%) 0.002 17 (11%) 47 (29%) <0.001 64 (21%)
Two consecutive VL 1,000 copies/ml through 12
months postpartum
10 (8%) 20 (15%) 0.119 12 (8%) 29 (18%) 0.011 41 (13%)
Data given as number (percent) unless otherwise indicated.
VL, viral load.
https://doi.org/10.1371/journal.pmed.1002547.t002
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Fig 3. Forest plot of primary outcome across a priori subgroups of demographic and clinical characteristics. ARV, antiretroviral.
https://doi.org/10.1371/journal.pmed.1002547.g003
Table 3. Results of additive binomial models examining the association between trial arm and primary outcome adjusted for demographic and clinical characteris-
tics (n = 411).
Characteristic Unadjusted models Adjusted model
Risk difference 95% confidence interval Risk difference 95% confidence interval
Trial arm (intervention minus control) 0.208 0.108 to 0.308 0.163 0.076 to 0.251
Maternal age (years) 0.016 0.007 to 0.023 0.013 0.009 to 0.017
Married or cohabiting (versus single) 0.102 −0.000 to 0.204 0.026 0.003 to 0.049
Newly diagnosed with HIV during pregnancy 0.033 −0.071 to 0.138 0.034 −0.021 to 0.089
Gestational age at ART initiation (weeks) −0.007 −0.014 to −0.001 −0.010 −0.013 to −0.006
ART initiation under Option B+ (versus Option A) 0.061 −0.076 to 0.198 0.025 −0.089 to 0.140
Previous TB diagnosis (versus no previous TB diagnosis) −0.183 −0.362 to −0.005 −0.149 −0.288 to −0.011
Viral load at randomisation (log10 copies/ml) −0.178 −0.240 to −0.117 −0.157 −0.189 to −0.125
Duration of ART use at time of outcome assessment (weeks) 0.001 −0.004 to 0.007 −0.006 −0.010 to −0.002
Adjusted model includes all covariates shown.
TB, tuberculosis.
https://doi.org/10.1371/journal.pmed.1002547.t003
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among women randomised to the MCH-ART arm than among those randomised to the SOC
arm in the total trial population (6.9 versus 3.0 months; p = 0.006) and when restricted to
women initiating ART under Option B+ (6.0 versus 3.0 months; p = 0.023). By 12 months
Fig 4. Time to cessation of any breastfeeding for women in the intervention and control arms. Log-rank test, p =
0.006.
https://doi.org/10.1371/journal.pmed.1002547.g004
Fig 5. Time to cessation of exclusive breastfeeding for women in the intervention and control arms. Log-rank, p<
0.001.
https://doi.org/10.1371/journal.pmed.1002547.g005
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postpartum, 16% in the MCH-ART arm and 12% in the SOC arm reported still breastfeeding
in the total trial population. The duration of EBF was shorter but followed a similar pattern,
with a median of 3.0 months in the MCH-ART arm versus 1.4 months in the SOC arm (p<
0.001) in the total trial population.
Table 4 compares MCH outcomes between trial arms, which did not differ significantly
between the intervention and control arms. Among 478 infants in the study, there were 9
deaths and 5 HIV infections observed in the first 12 months postpartum. Overall HIV-free sur-
vival through 12 months of age was 97%: mother-to-child HIV transmission at 12 months was
1.2% overall (comparison by trial arm, p = 0.178), and infant mortality was 1.9% (comparison
by trial arm, p = 0.296).
Discussion
This study demonstrates that integration of ART services into the MCH platform can lead to
significant improvements in HIV+ women’s retention in care and VS up to 12 months post-
partum. We also found longer durations of any BF and EBF among women who were rando-
mised to integrated MCH and ART services. Overall, the integration of MCH and ART
services may represent a simple intervention that can enhance the health of HIV+ women and
their children in the first year after delivery.
This is one of the few randomised studies presenting evidence that integration of MCH and
ART services can enhance women’s engagement in HIV care during the postnatal period and
improve biomedical outcomes. While the challenges of retention in care and adherence to
ART in HIV+ women during the postnatal period have been widely documented, rigorously
Table 4. Comparison of secondary outcomes between the intervention and control arms.
Outcome Total: all
participants











Number of infants born to study 478 187 199 236 242
Number of infant deaths 9a 5 3 6a 3a
Infant mortality through 12 months
postpartum
0.019 0.027 0.015 0.419 0.025 0.012 0.296
Number of infants with HIV diagnostic test
results available
461 183 193 229 232
Number of infant HIV infections 5b 3 1 4b 1b
Infant HIV transmission through 12
months postpartum
0.012 0.018 0.007 0.304 0.019 0.005 0.178
Routine 6–10-week infant HIV diagnostic
test results recorded in Road to Health
Bookletc
189 (76%) 102 (88%) 51 (58%) <0.001 127 (87%) 62 (60%) <0.001
Co-trimoxazole received at 6 weeks of age
(among breastfed infants)d
329 (83%) 144 (88%) 131 (82%) 0.217 174 (85%) 155 (80%) 0.206
Maternal family planning use at 12 months
postpartume
341 (83%) 138 (87%) 139 (81%) 0.107 169 (85%) 172 (82%) 0.483
Data given as number (percent) unless otherwise indicated.
aInfant deaths at 26, 30, 54, 62, 187, and 317 days of age (n = 6) in the intervention arm and at 45, 145, and 365 days (n = 3) in the control arm.
bInfants testing HIV-positive at 11, 12, 101, and 220 days of age (n = 4) in the intervention arm and at 308 days (n = 1) in the control arm.
cOf n = 249 infants with routine HIV diagnostic testing conducted in laboratory.
dOf n = 398 infants breastfed at 6 weeks postpartum and thus eligible for co-trimoxazole.
eOf n = 411 women with complete endpoint data.
https://doi.org/10.1371/journal.pmed.1002547.t004
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evaluated interventions to strengthen women’s engagement in services are scant. Existing
intervention modalities typically target individual women as the locus of intervention, for
example through intensified patient counselling, mobile health interventions, services offered
by lay health workers, and/or incentivising health behaviours, often with mixed results over
short durations postpartum [11]. While these approaches may be useful to address single, spe-
cific causes of women’s disengagement from care, the intervention effects observed to date
have been modest, and the feasibility of scaling up these interventions remains unclear.
In contrast, the integration of services represents a structural health systems intervention
that may impact on multiple aspects of service engagement. We observed strong associations
involving the primary outcome, women’s retention in care, and VS, as well as infant feeding
practices; we had limited power to detect associations with outcomes that occur more com-
monly (such as maternal family planning use) or rarely (such as mother-to-child HIV trans-
mission) in this setting. While not all research has shown improvements in care associated
with integration of HIV and MCH services [22], our results are congruent with previous find-
ings that models of care for postnatal ART services can influence outcomes for HIV+ women
and their families. One health services evaluation from Malawi suggested that clinics that com-
bined maternal and infant care yielded superior maternal retention outcomes compared to dis-
aggregated forms of care where mothers received treatment within general adult ART services
[14]. Similarly, a randomised controlled trial in Nigeria found significant increases in maternal
retention in HIV care up to 3 months postpartum with a multicomponent package interven-
tion that included co-scheduling of care for HIV+ mothers and their infants [23]. Building on
these results, our trial findings advance the state of knowledge by providing compelling evi-
dence demonstrating the specific effects of integrated postnatal services on multiple MCH
outcomes.
The differences observed in the primary outcome between the intervention and control
arms were generally similar across a range of subgroups. Of note, there is considerable interest
in the impact of ART initiation on the same day as the first ANC visit, compared to delaying
ART initiation to allow time for patient preparation [24]; we found the intervention effect per-
sisted regardless of this timing. Moreover, it is plausible that women who are newly diagnosed
with HIV in pregnancy may face particular challenges in ART retention and adherence,
though intervention effects were similar regardless of when women were diagnosed with HIV
infection. In addition, there are special concerns around the provision of lifelong ART for
young pregnant and postpartum women [25], but here the intervention effects were consistent
across all age groups.
We found that the strength of the intervention effect varied according to the amount of
time postpartum spent in the intervention service in a graded manner: the largest improve-
ments in the primary outcome were observed among women retained in the intervention
beyond 9 months postpartum, with smaller but appreciable differences observed in women
retained for 3 to 9 months. Meanwhile, among women in the intervention arm referred out to
general ART services before 3 months postpartum, outcomes measured at 12 months postpar-
tum were identical to those observed in the control arm. From these findings, we hypothesize
that the integrated care intervention may provide a critical foundation for establishing and
maintaining positive ART-related behaviours [26]. Related to this, we observed the strongest
intervention effects in women who initiated ART later in pregnancy—a high-risk group that
warrants special attention [27]. Specifically, women who started ART earlier in pregnancy, and
thus spent more time establishing positive ART-related behaviours before delivery, may have
benefitted less from remaining engaged in the integrated MCH-ART intervention service for
longer durations postpartum. In contrast, women initiating ART later in pregnancy may have
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experienced greater benefit from the longer durations spent in the integrated service afforded
by the intervention.
Alternate explanations for several findings warrant consideration. It is possible that some
part of the intervention effect may be attributable to delaying the referral of women out of the
MCH setting to adult ART clinics. Women retained in the intervention service after 9 months
would have had less opportunity to disengage from care before the outcome visit at 12 months
postpartum, though this would not explain the intervention effect observed among women
referred out before 9 months. Here, we used 12 months postpartum for the primary outcome
as most breastfeeding ends before this time in this setting, but it is critical to note that breast-
feeding and mother-to-child transmission risk may be for longer periods, and challenges in
maternal non-adherence and non-retention in services extend beyond this window. The trans-
fer of patients between chronic care services is recognised as a high-risk window for non-
adherence and non-retention [15,28], and longer durations of follow-up will be required to
evaluate whether the effects of the intervention appear in keeping with this hypothesis. In addi-
tion, it is possible that differential availability of routine care data across health facilities in this
setting could have explained some of the differences observed in retention outcomes between
the intervention and control arms. However, we note consistency in the retention findings
according to routine data source used, and further consistency with directly measured VS out-
comes, making this explanation unlikely.
There are a range of mechanisms that may have contributed to the improved maternal
health outcomes associated with the integrated services assessed here. The co-location of
maternal and infant care may lower the burden of clinic visits, reducing the time and eco-
nomic costs of healthcare attendance. For some women, receiving ART in the MCH setting
may be associated with less HIV-related stigma compared to general adult ART services, and
thus be more acceptable. In addition, nurse-midwives and other MCH providers may main-
tain better relationships with postpartum women, and in turn be better able to promote posi-
tive health behaviours. While these and other mechanisms warrant investigation, we posit that
the reasons why integrated services lead to improved health outcomes are likely to be diverse
and multifactorial, with different women benefitting from different aspects of integrated care
for different reasons.
This study also provides novel evidence that integrated postnatal services are associated
with prolonged breastfeeding, including EBF, by HIV+ women. Our finding may be unsur-
prising given the emphasis on breastfeeding within MCH services, in marked contrast to gen-
eral adult services, where infant feeding practices may receive less attention [29]. While the
relatively short overall duration of breastfeeding in this setting is in keeping with local norms,
the trial’s findings of longer breastfeeding and higher levels of VS in women randomised to the
MCH-ART intervention suggest that such integrated models of postnatal care may play an
important role in implementing new WHO infant breastfeeding policies [21]. Furthermore,
we found that the integrated MCH-ART service was associated with higher levels of recording
of routine early infant diagnostic testing for HIV; given the challenges in implementing effec-
tive infant testing services in many settings [30], this is an important feature that warrants fur-
ther investigation.
Several strengths and limitations require attention in interpreting these data. The trial took
place in primary care public sector services in a single part of South Africa, and as with any
health systems intervention, the generalisability of results should be considered with caution.
The control condition used here needs particular consideration when seeking to extrapolate
these results regarding the effects of integrated services. The SOC here may be broadly repre-
sentative of how MCH and ART are provided across urban and high-burden areas of South
Africa and southern Africa. However, this is not the SOC in all countries, and in different
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settings there may be other models of delivering integrated postnatal MCH and HIV care to
mothers and infants, particularly in smaller primary care facilities. In this light, we suggest that
the key findings here are for the value of integrated service delivery approaches for providing
care in the postnatal period, rather than suggesting a single, universally ideal model of care. To
evaluate the intervention, we used a novel composite primary endpoint incorporating both
healthcare utilisation and the key biomarker of interest in HIV treatment, VL, though few
interventions in this field have utilised such robust measures. We examined outcomes through
12 months postpartum—among the longest postpartum evaluations to date—but given that
ART is lifelong, investigations of extended outcomes for both mothers and children are war-
ranted. Here breastfeeding data were self-reported by mothers, raising ubiquitous concerns
around biased reporting [31], though our study visits took place separately from routine care
to help minimise such errors. Of note, this intervention does not address the phenomenon of
loss to follow-up during pregnancy immediately after ART initiation, which is a separate and
important consideration [8,14]. As discussed above, this trial only examines outcomes through
12 months postpartum, and the outcomes of transfers after that period require further investi-
gation. Finally, the acceptability of service integration among patients and providers, as well as
costs and cost-effectiveness, are important considerations not addressed in these data, but will
be important avenues for future research.
In summary, these findings have substantial implications for policy and programme design.
With few previous insights into the integration of HIV care into postnatal MCH settings, this
study demonstrates that integrating ART services into the MCH platform for the duration of
breastfeeding may be a simple and effective intervention for improving MCH outcomes in the
context of HIV.
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